Blab Business
Readcrest Capital AG Forecasts 2026 Adjusted EBITDA of 8-9 Million After UK Care Home Sale
On June 7, 2026, Readcrest Capital AG – the German investment group listed on the Frankfurt Stock Exchange – released a forward‑looking view that its adjusted earnings before interest, taxes, depreciation and amortisation (EBITDA) for fiscal 2026 will fall between €8.0 million and €9.0 million. The guidance, issued by the company’s management board, reflects the new balance sheet that emerged after the divestiture of its UK care‑home subsidiary.
In April, Readcrest sold the UK arm that operated long‑term care homes for an initial consideration of £44 million, roughly €50.6 million. Management said the proceeds would be used to trim debt, acquire smaller UK home‑care operators and fund German real‑estate projects.
The forecast hinges largely on Grosvenor Health and Social Care, a core portfolio company that is expected to contribute about €12 million to adjusted EBITDA. German project developments, on the other hand, are projected to subtract between €3 million and €4 million, leaving the net range of €8.0 million to €9.0 million.
Readcrest clarified that adjusted EBITDA is an unaudited metric, not defined under IFRS. It is calculated as operating profit plus depreciation and amortisation, with adjustments for significant non‑recurring items such as impairment losses on receivables or inventory, and the removal of gains from the write‑off of liabilities. The calculation deliberately excludes the sold care‑home business to isolate underlying operating profitability.
The company’s strategy now places greater emphasis on two growth pillars. Grosvenor Health and Social Care remains the bulk of operating revenue and cash flow, while the second pillar focuses on value‑oriented real‑estate investments, particularly residential construction projects in high‑growth regions of Germany. Readcrest has announced a systematic expansion of this real‑estate segment, citing the potential for stable returns in the German market.
The forecast comes as Readcrest’s share price trades around €1.47 on the Frankfurt exchange. Market observers have viewed the sale of the UK care‑home business as a move to streamline the portfolio and concentrate on higher‑margin operations.
Investors will watch the company’s upcoming earnings report for 2026 to see whether actual adjusted EBITDA aligns with the forecasted range. While the company has not yet provided detailed guidance on cash‑flow projections or debt‑service coverage, the sale proceeds and the focus on Grosvenor and German real‑estate projects suggest a conservative outlook.
In summary, Readcrest Capital AG expects its adjusted EBITDA for 2026 to be between €8.0 million and €9.0 million, driven largely by Grosvenor Health and Social Care after the divestiture of its UK care‑home business. The company is expanding its real‑estate investment activities in Germany while maintaining a focus on stable, cash‑generating operations.
The next key event for the company will be its 2026 earnings announcement, expected in the first quarter of 2027. Market participants will also be interested in any further developments regarding the use of the sale proceeds, potential acquisitions in the UK care‑home sector, and progress on the German residential construction projects.
In April, Readcrest sold the UK arm that operated long‑term care homes for an initial consideration of £44 million, roughly €50.6 million. Management said the proceeds would be used to trim debt, acquire smaller UK home‑care operators and fund German real‑estate projects.
The forecast hinges largely on Grosvenor Health and Social Care, a core portfolio company that is expected to contribute about €12 million to adjusted EBITDA. German project developments, on the other hand, are projected to subtract between €3 million and €4 million, leaving the net range of €8.0 million to €9.0 million.
Readcrest clarified that adjusted EBITDA is an unaudited metric, not defined under IFRS. It is calculated as operating profit plus depreciation and amortisation, with adjustments for significant non‑recurring items such as impairment losses on receivables or inventory, and the removal of gains from the write‑off of liabilities. The calculation deliberately excludes the sold care‑home business to isolate underlying operating profitability.
The company’s strategy now places greater emphasis on two growth pillars. Grosvenor Health and Social Care remains the bulk of operating revenue and cash flow, while the second pillar focuses on value‑oriented real‑estate investments, particularly residential construction projects in high‑growth regions of Germany. Readcrest has announced a systematic expansion of this real‑estate segment, citing the potential for stable returns in the German market.
The forecast comes as Readcrest’s share price trades around €1.47 on the Frankfurt exchange. Market observers have viewed the sale of the UK care‑home business as a move to streamline the portfolio and concentrate on higher‑margin operations.
Investors will watch the company’s upcoming earnings report for 2026 to see whether actual adjusted EBITDA aligns with the forecasted range. While the company has not yet provided detailed guidance on cash‑flow projections or debt‑service coverage, the sale proceeds and the focus on Grosvenor and German real‑estate projects suggest a conservative outlook.
In summary, Readcrest Capital AG expects its adjusted EBITDA for 2026 to be between €8.0 million and €9.0 million, driven largely by Grosvenor Health and Social Care after the divestiture of its UK care‑home business. The company is expanding its real‑estate investment activities in Germany while maintaining a focus on stable, cash‑generating operations.
The next key event for the company will be its 2026 earnings announcement, expected in the first quarter of 2027. Market participants will also be interested in any further developments regarding the use of the sale proceeds, potential acquisitions in the UK care‑home sector, and progress on the German residential construction projects.
